(Q37576105)

21 August 2017

1 reference

title

Fibrate therapy and renal function (English)

1 reference

21 August 2017

Domenic A Sica

1

1 reference

PubMed ID

19664376

21 August 2017

language of work or name

1 reference

1 September 2009

1 reference

Current Atherosclerosis Reports

21 August 2017

1 reference

21 August 2017

11

1 reference

21 August 2017

5

1 reference

21 August 2017

338-342

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-009-0051-5

21 August 2017

0 references

cites work

Safety issues and prospects for future generations of PPAR modulators

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0051-5

Fibrate-induced increase in blood urea and creatinine

21 January 2018

1 reference

12 December 2020

Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate

1 reference

12 December 2020

Cimetidine improves the reliability of creatinine as a marker of glomerular filtration

1 reference

12 December 2020

Pleiotropic effects of fenofibrate

1 reference

12 December 2020

Pharmacology of fenofibrate

1 reference

12 December 2020

Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients

1 reference

12 December 2020

Falsely-elevated serum creatinine values in diabetic ketoacidosis -- clinical implications

1 reference

12 December 2020

Fibrate treatment can increase serum creatinine levels

1 reference

12 December 2020

Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease

1 reference

12 December 2020

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

1 reference

12 December 2020

Safety considerations with fibrate therapy

1 reference

12 December 2020

Fenofibrate-Induced elevation in serum creatinine

1 reference

12 December 2020

Deterioration in renal function associated with fibrate therapy.

1 reference

12 December 2020

Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay

1 reference

12 December 2020

Fibrate-associated adverse effects beyond muscle and liver toxicity

1 reference

12 December 2020

Fibrate-induced increase in serum urea and creatinine levels.

1 reference

12 December 2020

The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients.

1 reference

12 December 2020

Renal function changes in diabetic nephropathy induced by bezafibrate

1 reference

12 December 2020

The effects of medications used for the management of dyslipidemia on postprandial lipemia

1 reference

12 December 2020

Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials

1 reference

12 December 2020

Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency

1 reference

12 December 2020

Creatinine rise after fibrate therapy in renal graft recipients

1 reference

12 December 2020

Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people

1 reference

12 December 2020

Managing dyslipidemia in chronic kidney disease.

1 reference

12 December 2020

Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

1 reference

12 December 2020

Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations

1 reference

12 December 2020

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

12 December 2020

Serum creatinine as an index of renal function: new insights into old concepts.

1 reference

12 December 2020

A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate

1 reference

12 December 2020

Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes

1 reference

12 December 2020

Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.

1 reference

12 December 2020

Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity

1 reference

12 December 2020

Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency

1 reference

12 December 2020

Fenofibrate increases creatininemia by increasing metabolic production of creatinine

1 reference

12 December 2020

The effect of renal function on the pharmacokinetics of gemfibrozil

1 reference

12 December 2020

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

1 reference

12 December 2020

Fibrate therapy: an update

1 reference

12 December 2020

Severe reversible renal failure with bezafibrate.

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

10.1007/S11883-009-0051-5

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19664376